Every piece MicroCap Desk has published on Adagene, newest first. Independent editorial — we take no compensation from the companies we cover.
Adagene has a new Incyte cancer collaboration and about $128M in cash. Validation plus a long runway.
How masked-antibody design aims to spare healthy tissue in cancer immunotherapy.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.